Glaxosmithkline Share News (GSK)

UPDATE 1-FDA proposes adding suffixes to distinguish biosimilar drug names

(Adds industry, patient group comment) By Toni Clarke WASHINGTON, Aug 27 (Reuters) - The U.S. Food and Drug Administration proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts. The

FDA proposes adding suffixes to distinguish biosimilar drug names

WASHINGTON, Aug 27 (Reuters) - Cheaper versions of biologic drugs would be identified by a suffix to distinguish them from their more expensive, branded counterparts under draft guidance issued on Thursday by the U.S. Food and Drug Administration. The FDA said its proposal is designed to

BUZZ-U.S. STOCKS ON THE MOVE-Apple, SunEdison, HMS Holdings, Abercrombie

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock indexes were down on Monday. The Dow Jones industrial a

BUZZ-U.S. STOCKS ON THE MOVE-Bank stocks, tech stocks, AGL, ChinaCache

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock indexes were down on Monday. The Dow Jones industrial a

BUZZ-Healthcare stocks: Down on market selloff

** Shares of healthcare companies including drugmakers and biotechnology therapy developers fall about 3 pct as Wall Street opens sharply lower ** More than 8 pct drop in Chinese shares, selloff in oil and other commodities prompt downturn in all three stock market indices ** U.S.-lis

EU Commission clears Perrigo to buy GSK units

BRUSSELS, Aug 21 (Reuters) - The European Commission cleared on Friday U.S. drugmaker Perrigo's acquisition of certain assets from Britain's GSK. The Commission, in its role as the competition regulator in the 28-member European Union, said GSK would sell certain products such as cold and f

TOP NEWS SUMMARY: UK Records First July Budget Surplus Since 2012

LONDON BRIEFING: China And Greece Combine To Send Stocks Reeling

GSK extends Novartis disposal agreement

(ShareCast News) - GlaxoSmithKline has sold all the rights to its ofatumumab drug to Novartis for up to £1.03bn, extending a previous disposal agreement. GSK previously agreed to divest the drug's oncology indications and has now agreed to include its rights in ofatumumab for auto-immune indications

London pre-open: stocks set to plunge as China off the rails

(ShareCast News) - City sources predict the FTSE 100 will open 142 points lower than Thursday's close of 6,367.89. "European equities are set to plunge on the open as China goes off the rails," London Capital Group night dealer Jonathan Sudaria said. Sudaria said bulls were already slowed by a barr

UPDATE 1-Novartis buys remaining rights to GSK treatment for up to $1 bln

* Will make initial $300 mln payment to buy compound * Further $200 mln after start of a phase III study * Up to $534 mln to be paid if milestones met * Will pay royalties of up to 12 pct on future net sales (Adds comment from head of Novartis Pharmaceuticals, detail) ZU

Novartis buys remaining rights to GSK treatment in deal up to $1 bln

ZURICH, Aug 21 (Reuters) - Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline. Basel-based Novartis will make a

Glaxo Sells Ofatumumab Auto-Immune Indication Rights To Novartis

EU mergers and takeovers (Aug 18)

BRUSSELS, Aug 18 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS none NEW LISTINGS -- Pfizer to acquire British drugmaker GlaxoSmithKline's menACWY meningitis vaccine busine

GSK hopes big clinical trial can breath new life into lung drug

* Results of SUMMIT trial with Breo due as early as Sept * Drug could be first to extend lives in COPD * Billions of dollars riding on positive outcome * U.S. partner Theravance eligible for royalties on sales By Ben Hirschler LONDON, Aug 13 (Reuters) - GlaxoSmithKli